Correction to: Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

Adv Ther. 2019 Oct;36(10):2927-2929. doi: 10.1007/s12325-019-01082-6.

Authors

Marilyn K Glassberg¹, Steven D Nathan², Chin-Yu Lin³, Elizabeth A Morgenthien³, John L Stauffer³, Willis Chou⁴, Paul W Noble⁵

Affiliations

¹ University of Miami Health System, Miami, FL, USA. MGlassbe@med.miami.edu.
² Inova Fairfax Hospital, Falls Church, VA, USA.
³ Genentech, Inc., South San Francisco, CA, USA.
⁴ FibroGen, San Francisco, CA, USA.
⁵ Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Abstract

In the Original Publication the colors of Figure 2 have been switched. The correct figures are given below.

Publication types

Published Erratum